Drugs /

mivebresib

Back to Drugs List

Overview

NCI Definition [1]:
An inhibitor of one or more as of yet undisclosed bromodomain (BRD)-containing protein(s), with potential antineoplastic activity. Upon administration, the bromodomain inhibitor ABBV-075 binds to the acetyl-lysine binding site in the BRD of certain BRD-containing protein(s), thereby preventing the interaction between those proteins and acetylated histones. This disrupts chromatin remodeling, prevents the expression of certain growth-promoting genes, and leads to an inhibition of cell growth in susceptible tumors.

Clinical Trials

View Clinical Trials for mivebresib

Mivebresib has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating mivebresib, 1 is phase 1 (1 open).

KMT2A Fusion, KMT2A-AFF1 Fusion, and KMT2A-ELL Fusion are the most frequent biomarker inclusion criteria for mivebresib clinical trials.

Myelofibrosis transformation in essential thrombocythemia, polycythemia vera, post-polycythemic myelofibrosis phase, and primary myelofibrosis are the most common diseases being investigated in mivebresib clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Mivebresib
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating mivebresib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,931 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
bromodomain inhibitor abbv-075, abbv-075
Drug Target(s) [2]:
BRD2, BRD3, BRD4, BRDT
NCIT ID [1]:
C121829

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.